Target Name: WAKMAR2
NCBI ID: G100130476
Review Report on WAKMAR2 Target / Biomarker Content of Review Report on WAKMAR2 Target / Biomarker
WAKMAR2
Other Name(s): lnc-TNFAIP3 | wound and keratinocyte migration associated lncRNA 2 | Wound and keratinocyte migration associated lncRNA 2

WAKMAR2: A Potential Drug Target and Biomarker

WAKMAR2, a gene named after its associated protein, has been identified as a potential drug target and biomarker for various diseases. Its unique structure and function have made it an attractive target for scientists and researchers to investigate.

WAKMAR2 is a protein that is expressed in many different tissues and cells in the body. It is a key regulator of the immune response and has been linked to various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

One of the most significant aspects of WAKMAR2 is its role in the immune response. It is a key regulator of the development and function of T cells, which are a critical part of the immune system. T cells are responsible for recognizing and responding to foreign substances in the body, including viruses and bacteria.

WAKMAR2 has been shown to play a crucial role in regulating the growth and development of T cells. It has been shown to promote the expansion and maturation of T cells, as well as the production of antibodies that help to neutralize toxins and viruses.

In addition to its role in the immune system, WAKMAR2 has also been linked to various diseases. For example, it has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's. It has also been linked to various autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

As a potential drug target, WAKMAR2 has the potential to treat a wide range of diseases. For example, it could be used to treat neurodegenerative diseases by targeting and blocking the activity of WAKMAR2. It could also be used to treat autoimmune disorders by inhibiting the activity of WAKMAR2 and preventing the formation of immune complexes that can cause damage to the body.

In addition to its potential as a drug target, WAKMAR2 has also been identified as a potential biomarker. Its expression has been shown to be elevated in a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. This makes it an attractive target for researchers to investigate the role of WAKMAR2 in these diseases and to develop new diagnostic tools.

WAKMAR2 has also been shown to have potential as a therapeutic agent. For example, studies have shown that inhibiting the activity of WAKMAR2 can protect against neurodegenerative diseases, such as Alzheimer's and Parkinson's. Additionally, it has been shown to have anti-inflammatory effects and to protect against oxidative stress, which can contribute to the development of various diseases.

In conclusion, WAKMAR2 is a protein that has the potential to be a drug target and biomarker for a wide range of diseases. Its unique structure and function make it an attractive target for researchers to investigate and develop new treatments. Further studies are needed to fully understand the role of WAKMAR2 in the immune and inflammatory systems, as well as its potential as a therapeutic agent.

Protein Name: Wound And Keratinocyte Migration Associated LncRNA 2

The "WAKMAR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WAKMAR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WAPL | WARS1 | WARS2 | WARS2-AS1 | WAS | WASF1 | WASF2 | WASF3 | WASF4P | WASF5P | WASH complex | WASH2P | WASH3P | WASH4P | WASH5P | WASH6P | WASH7P | WASH8P | WASHC1 | WASHC2A | WASHC2C | WASHC3 | WASHC4 | WASHC5 | WASIR1 | WASL | WAVE1 complex | WBP1 | WBP11 | WBP11P1 | WBP1L | WBP2 | WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89